An experimental gene-silencing therapy safely lowered LRRK2 protein levels in an early Parkinson’s trial, but its effect on symptoms remains untested. An experimental medicine built to silence a gene closely associated with Parkinson’s disease has produced encouraging results in its first clinical test in people, according to a study published in Nature Medicine. The treatment, [...]